Low expression of bax predicts poor prognosis in resected non-small cell lung cancer patients with non-squamous histology

Japanese Journal of Clinical Oncology

Volumn 38, Issue 10, 2008, Pages 661-669

  Jeong, Seong Hyun ^a   Lee, Hyun Woo ^a   Han, Jae Ho ^a   Kang, Seok Yun ^a   Choi, Jin Hyuk ^a   Jung, Youn Mu ^a   Choi, Ho ^a   Oh, Young Taek ^a   Park, Kwang Joo ^a   Hwang, Sung Chul ^a   Sheen, Seung Soo ^a   Oh, Yoon Jung ^a   Kim, Jang Hee ^a   Lim, Ho Yeong ^b  

^a Ajou University School of Medicine   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Bax; Non small cell lung cancer; Prognosis

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; GALECTIN 3; GEMCITABINE; PROTEIN BAX; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BCL-2-ASSOCIATED X PROTEIN; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FEMALE; GALECTIN 3; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 54949143174     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyn089     Document Type: Article

References (32)

1. Bae J, Won Y, Jung K, Suh K, Yun Y, Shin M. Survival of Korean cancer patients diagnosed in 1995. Cancer Res Treat 2002;34:319-25.
2. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med 2004;350:379-92.
3. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710-7.
4. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-60.
5. Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589-97.
6. Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzales-Larriba JL, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): A randomised controlled trial. Lancet Oncol 2006;7:719-27.
7. Pignon J, Tribodet H, Scagliotti G. A pooled analysis of five randomized clinical trials including 4,584 patients. J Clin Oncol 2006;24(Suppl.):366.
8. Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006;25:4798-811.
9. Jurgensmeier JM, Xie Z, Deveraux Q, Ellerby L, Bredesen D, Reed JC. Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci USA 1998;95:4997-5002.
10. Yang RY, Liu FT. Galectins in cell growth and apoptosis. Cell Mol Life Sci 2003;60:267-76.
11. Singhal S, Vachani A, Antin-Ozerkis D, Kaiser LR, Albelda SM. Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: A review. Clin Cancer Res 2005;11:3974-86.
12. Zhu CQ, Shih W, Ling CH, Tsao MS. Immunohistochemical markers of prognosis in non-small cell lung cancer: A review and proposal for a multiphase approach to marker evaluation. J Clin Pathol 2006;59: 790-800.
13. Ling CC, Guo M, Chen CH, Deloherey T. Radiation-induced apoptosis: effects of cell age and dose fractionation. Cancer Res 1995;55: 5207-12.
14. Frederick L. AJCC Cancer Staging Manual. Lippincott Raven, 2002.
15. Kaplan E, Meier P. Non-parametric estimations from incomplete observations. J AM Stat Assoc 1958;53:457-81.
16. Cox D. Regression model and life-tables. J R Stat Soc Ser 1972;34:187-220.
17. Steels E, Paesmans M, Berghmans T. Role of P53 as a prognostic factor for survival in lung cancer: A systematic review of the literature with a meta-analysis. Eur Respir J 2001;18:705-19.
18. Lee JS, Yoon A, Kalapurakal SK, Ro JY, Lee JJ, Tu N, et al. Expression of p53 oncoprotein in non-small-cell lung cancer: A favorable prognostic factor. J Clin Oncol 1995;13:1893-903.
19. Apolinario RM, van der Valk P, de Jong JS, Deville W, van Ark-Otte J, Dingemans AM, et al. Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer. J Clin Oncol 1997;15:2456-66.
20. Borner MM, Brousset P, Pfanner-Meyer B, Bacchi M, Vonlanthen S, Hotz MA, et al. Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected non-small-cell lung cancer. Br J Cancer 1999;79:952-8.
21. Chen Y, Sato M, Fujimura S, Endo C, Sakurada A, Aikawa H, et al. Expression of Bcl-2, Bax, and p53 proteins in carcinogenesis of squamous cell lung cancer. Anticancer Res 1999;19:1351-6.
22. Groeger AM, Esposito V, De Luca A, Cassandro R, Tonini G, Ambrogi V, et al. Prognostic value of immunohistochemical expression of p53, bax, Bcl-2 and Bcl-xL in resected non-small-cell lung cancers. Histopathology 2004;44:54-63.
23. Szoke T, Kayser K, Baumhakel JD, Trojan I, Furak J, Tiszlavicz L, et al. Prognostic significance of endogenous adhesion/growth-regulatory lectins in lung cancer. Oncology 2005;69:167-74.
24. Szoke T, Kayser K, Trojan I, Kayser G, Furak J, Tiszlavicz L, et al. The role of microvascularization and growth/adhesion-regulatory lectins in the prognosis of non-small cell lung cancer in stage II. Eur. J Cardiothorac Surg 2007;31:783-7.
25. Puglisi F, Minisini AM, Barbone F, Intersimone D, Aprile G, Puppin C, et al. Galectin-3 expression in non-small cell lung carcinoma. Cancer Lett 2004;212:233-9.
26. Porebska I, Wyrodek E, Kosacka M, Adamiak J, Jankowska R, Harlozinska-Szmyrka A. Apoptotic markers p53, Bcl-2 and Bax in primary lung cancer. In Vivo 2006;20:599-604.
27. Christiani DC PW, DeMartini JC, Linnoila RI, Malkinson AM, Onn A, Politi KA, et al. BAC consensus conference, November 4-6, 2004: Epidemiology, pathogenesis, and preclinical models. J Thorac Oncol 2006;1(Suppl. 9):S2-7.
28. Tanaka R, Ishiyama T, Uchihara T, Inadome Y, Iijima T, Morishita Y, et al. Expression of the Bax inhibitor-1 gene in pulmonary adenocarcinoma. Cancer 2006;106:648-53.
29. Gessner C, Liebers U, Kuhn H, Stiehl P, Witt C, Schauer J, et al. BAX and p16INK4A are independent positive prognostic markers for advanced tumour stage of nonsmall cell lung cancer. Eur Respir J 2002;19:134-40.
30. Hanaoka T, Nakayama J, Haniuda M, Sato T. Immunohistochemical demonstration of apoptosis-regulated proteins, Bcl-2, and Bax, in resected non-small-cell lung cancers. Int J Clin Pract 2002;7:152-8.
31. Yaren A, Oztop I, Kargi A. Bax, bcl-2, and c-kit expression in non-small-cell lung cancer and their effects on prognosis. Int J Clin Pract 2006;60:675-82.
32. Kang SY, Han JH, Lee KJ, Choi JH, Park JI, Kim HI, et al. Low expression of Bax predicts poor prognosis in patients with locally advanced esophageal cancer treated with definitive chemoradiotherapy. Clin Cancer Res 2007;13:4146-53.